VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 14 filers reported holding VERONA PHARMA PLC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,976 | -89.5% | 428 | -86.4% | 0.00% | -100.0% |
| Q2 2023 | $66,337 | +72797.8% | 3,138 | -30.8% | 0.00% | -33.3% |
| Q1 2023 | $91 | +378.9% | 4,534 | +520.2% | 0.00% | +200.0% |
| Q4 2022 | $19 | -99.7% | 731 | +32.2% | 0.00% | – |
| Q3 2022 | $6,000 | -25.0% | 553 | -74.0% | 0.00% | – |
| Q2 2022 | $8,000 | +60.0% | 2,126 | +106.2% | 0.00% | – |
| Q1 2022 | $5,000 | +150.0% | 1,031 | +209.6% | 0.00% | – |
| Q4 2021 | $2,000 | -80.0% | 333 | -81.3% | 0.00% | – |
| Q3 2021 | $10,000 | +11.1% | 1,777 | +30.2% | 0.00% | – |
| Q2 2021 | $9,000 | +800.0% | 1,365 | +582.5% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 200 | -23.7% | 0.00% | – |
| Q2 2019 | $1,000 | -50.0% | 262 | -28.4% | 0.00% | – |
| Q1 2019 | $2,000 | -50.0% | 366 | -17.2% | 0.00% | – |
| Q4 2018 | $4,000 | +33.3% | 442 | +73.3% | 0.00% | – |
| Q3 2018 | $3,000 | 0.0% | 255 | 0.0% | 0.00% | – |
| Q2 2018 | $3,000 | -66.7% | 255 | -45.7% | 0.00% | -100.0% |
| Q1 2018 | $9,000 | +200.0% | 470 | +136.2% | 0.00% | – |
| Q3 2017 | $3,000 | – | 199 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 2,457,499 | $16,932,000 | 5.79% |
| Aisling Capital Management LP | 1,332,485 | $9,327,000 | 1.60% |
| Ghost Tree Capital, LLC | 810,000 | $5,670,000 | 1.26% |
| Vivo Capital, LLC | 3,048,507 | $21,340,000 | 0.95% |
| NEA Management Company, LLC | 5,108,563 | $35,760,000 | 0.94% |
| Novo Holdings A/S | 2,608,755 | $18,261,000 | 0.78% |
| Samsara BioCapital, LLC | 1,111,112 | $7,778,000 | 0.78% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,033,603 | $7,235,000 | 0.64% |
| RA Capital Management | 5,100,000 | $31,824,000 | 0.44% |
| Orbimed Advisors | 5,694,841 | $39,864,000 | 0.35% |